Zelda Therapeutics makes significant progress in medicinal cannabis research programs

Zelda Therapeutics makes significant progress in medicinal cannabis research programs

Listed medicinal cannabis company Zelda Therapeutics (ASX: ZLD) has made progress in a number of key research programs during the March 2018 financial quarter.

Zelda recently received approval for a major study into the pharmacology of cannabinoids in the treatment of paediatric autism patients.

The study is set to be conducted at the USA-based Children's Hospital of Philadelphia, and Zelda says it is a key milestone in ongoing medical cannabis research in a clinical environment.

The group has also expanded its pre-clinical pancreatic cancer research programme with Curtin University.

The study focuses on live animal studies to investigate the effect of a range of the group's formulations in combination with existing chemotherapy agents.

Zelda says animal research is a major precursor to future human clinical trials.

During the last quarter, the group announced the initiation of a new pre-clinical research programme exploiting the potential for certain cannabinoids formulations to reduce the impact of diabetes-associated cognitive decline.

This study is also being conducted in partnership with Curtin University.

Zelda says it has made "excellent" progress on its clinical trial that is investigating the effect of medicinal marijuana on people with chronic insomnia symptoms.

Outside of the research and development sphere, Zelda has been approved for trading on the OTCQB Venture Market in the USA under the symbol ZLDAF.

The OTCQB is a US-based trading platform for early-stage and developing USA and international companies.

Through this new market, the group aims to grow its access to the US investment community.

Executive chairman Harry Karelis said he was pleased with Zelda's performance in the March quarter.

"We have made an excellent start to 2018 with significant progress on multiple research fronts autism, pancreatic cancer, insomnia and now cognitive decline," says Karelis.

"We firmly believe our approach is the correct strategy in an environment where regulators continue to tighten their oversight on groups making unsubstantiated claims for cannabinoid products."

Shares in Zelda Therapeutics closed at $0.12 per share on 27 April 2018.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Get our daily business news

Sign up to our free email news updates.

 
Whitefox Recruitment founder Luke Hemmings making strides as a careers leader
Partner Content
After relocating his Canberra-founded company Whitefox Recruitment to the Gold Coast la...
Whitefox Recruitment
Advertisement

Related Stories

ASIC secures its first court win for greenwashing against US giant Vanguard

ASIC secures its first court win for greenwashing against US giant Vanguard

The Australian corporate watchdog has caught out one of the world&r...

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Australian-founded medicinal cannabis company Althea Group (ASX: AG...

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Listed funds manager 360 Capital Group (ASX: TGP) has offloaded its...

Lendlease gains approval for $1.7b transformation of Queen Victoria Market precinct

Lendlease gains approval for $1.7b transformation of Queen Victoria Market precinct

Australian development giant Lendlease Group (ASX: LLC) has been gr...